Vicore Pharma Holding AB (publ)

Research Vicore Pharma Holding AB (publ) (VICO) on Bullrun: market cap SEK 3.35B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerVICO
• ExchangeST
• CountrySweden
• SectorHealthcare
• IndustryBiotechnology
• CurrencySEK
• Market capSEK 3.35B
• Financial periodQ4 2025
• RevenueSEK 419.00K
• Net income-SEK 137.10M
• Free cash flow-SEK 81.48M
• Gross margin100.0%

Valuation Snapshot

latest market cap is SEK 3.35B.

About Vicore Pharma Holding AB (publ)

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.

Frequently asked questions

What is Vicore Pharma Holding AB (publ)'s market cap?

Vicore Pharma Holding AB (publ)'s market capitalization is SEK 3.35B.

What does Vicore Pharma Holding AB (publ) do?

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden.